Market News

Company moves away from manual processing in favour of automated, scalable platforms.

Company recognised for its innovation and continual delivery of new natural ingredients.

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.

The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.

The plant will be first-of-its-kind in the US.

Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.

One company's positive approach to Brexit preparations, despite the lack of definition.

I Holland to share their 70 years' experience in an ‘ultimate’ tooling seminar.

The EMA needs to provide more action and guidance to help UK pharmaceutical manufacturers, says Thomas Beck, senior vice president, quality management, Recipharm.

Dedicated facility developed in response to increasing demand for product development projects in diagnostics, R&D and bioprocess.

Pall and BioSciencesCorp unite to provide "total solutions" for today's drug manufacturers.

First CDMO in China that is approved to supply commercial APIs for innovative drugs by regulatory agencies in the US, China, EU, Canada, Switzerland, Australia, and New Zealand.

WuXi STA chosen for its end-to-end CMC platform for new drug development.

To meet new PV regulations, the industry has to face a "multitude of unknowns and an ever-moving target".

The AGF 5000 is a machine with a compact and space-saving design, easy handling and a small number of format parts.

The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

Action ensures that the US is prepared should smallpox be used as a bioweapon.

FDF launches at CPHI Korea as country set to become regional hub.

Company will offer compliant products to all markets, including Europe and the US.

Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, speaks to CPHI Online on the trends and challenges involved with conducting stability studies for firms that supply to multiple countries, and the advantages of using a contracto...

Winners will be announced live at the Gala Ceremony in Madrid with over 500 of Pharma’s top executives.

Company will be able to add 2D codes, human-readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.

Packaging technology is not a core Bosch business.

The latest developments in process development, nucleation control, scale-up of freeze drying cycles and development in lyophilization technology.

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Company's Wear Indicator Layer attracts the most attention.

Company consolidated as one of the leading laboratories in weight control thanks to the development of its existing range and new launches.

The topical treatment for hair loss boasts a 'commercial' formulation.

Experts warn bio industry needs to do more to create a sustainable pipeline of talent.

Ruling prevents Dr Reddy's Laboratories will from launching their alternative salt forms of pemetrexed until the patent expires.

Approval for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome, two rare, severe childhood-onset epilepsies.

MedPharm licenses its MedSpray ‘Patch-in-a-Can’ technology to Virpax Pharmaceuticals.

Next expansion step will increase finished product capacity for recombinant proteins by more than tenfold.

The Rocket 4D Synergy uses proprietary vacuum technology to suppress solvent bumping and foaming.

Researchers to benefit by receiving a rapid and cost-effective scaled supply of new compounds.

Acquired business will enhance Recipharm’s scale and provide access to new customers and higher margin specialised technologies.

Agreement will enable customers to achieve easier scalability of processes ranging from lab-scale to commercial-scale production of biopharmaceuticals.

The India Expo Mart brings the event closer to Indian regulatory and legislative hub and will encourage international audiences.

The Wear Indicator Layer is expected to have a "huge impact" on customers' production.

Company has developed a standard feature for its customers to execute the EMVO conformance testing successfully.

TAOS matrix system and products hailed as potential ‘game changers’ in the field of regenerative medicine.

‘Brexit taskforce’ will see Recipharm prioritise its preparations and invest in the necessary capabilities and equipment to ensure seamless operations post March 2019.

Forgotten markets of Africa and Arabia to see increased growth fuelled by international and domestic partnerships and imported APIs.

Company to streamline operations and capture cost synergies.

Testa Anayltical to discuss their latest developments and application advances in Light Scattering technology, GPC/SEC instrumentation and Zeta potential measurement.

New equipment allows Genvion to take customers from development through to commercial manufacture.

Tjoapack to perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.

New poster describes how the EAF4 module enabled simultaneous measurement of size and surface charge characteristics of antibodies and proteins.

Bosch's new Xelum R&D for continuous production of oral solid dosage forms ensures a short time-to-market and optimum dosing of APIs.

2018 event prepares for surge in international attendees as MAH nears national rollout.

Postponement printing is presenting interesting benefits for the pharmaceutical supply chain.

With the capacity expansion, Thermo Fisher will have the second largest base of single-use bioproduction capacity at a CDMO in the world.

Acquisition of AurKa Pharma expands Lilly's oncology pipeline with early-phase asset being studied in multiple tumour types.

Recipharm's Staffan Widengren, Director Corporate Projects, discusses why CMOs should be focusing on the value-added opportunities presented by serialisation.

Allows for easy and intuitive scale-up from research.

Customers to gain a greater insight into their projects, better track project progress and improve communications.

Managing the risks associated with Industrial Hygiene and Quality and meeting operational efficiency targets.

New Industry 4.0 solutions from Bosch for more transparency.

Acquisition enables Ardena to manufacture batch sizes up to 100 kg.

Anmeal and Impax create diversified pharmaceutical company.

The integrated R&D and manufacturing facility is expecting more products to go into commercial production post approval.

Noramco and SPI Pharma sign agreement to develop ready-to-implement, patient-friendly formulations for pharmaceutical manufacturers.

Integrated one-site solution for partners to push forward innovative APIs and advanced intermediates from preclinical to commercial stage.

Energy efficient, short cycle times and reliable product quality in large batches.

Company to bring its new services and products into the spotlight at ACHEMA.

The CDMO's US sales have increased from £15.5 million to £41 million since 2016.

Sartorius Stedim Biotech introduces its mini microcarrier bioreactor for culturing adherent cells.

Investment enhances the CDMO's scale-up and small to midscale commercial API manufacturing capabilities.

The contract manufacturer strengthens its pharmaceutical-protein business with Dutch acquisition

MD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer.

Sale of oncology business unlocks embedded value within Shire’s portfolio and sharpens focus on core areas reinforcing the company's leadership in rare diseases.

Investment will focus on the rapid and successful development of processes to supply clinical and commercial demand for chemical syntheses.

Carbon footprint reduced by more than 70%.

Expansion meets the demand for additional capacity to serve large-scale clinical studies and provides the space for future growth.

NIH-funded study finds omega-3 fails to yield beneficial results in the clinic.

New Toronto facility is one of the largest-ever investments by Sanofi in a single building.

Purpose-built compliance solution for smaller pharmaceutical companies.

First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.

SVP250 LF processing system minimizes product loss thanks to conical vessel shape.

Revolutionary, innovative plant offers greater flexibility, speed and efficiency.

The event will annually switch between Indonesia and Thailand to cater to attendees that were previously unable to participate.

The IHD series has been specially designed for coating and granulating pharmaceutical products with hot greases and waxes.

Pharma Liquid World shows the connection of a preparation system and filling machine, as well as robotic technology in aseptic filling.

The company’s environmental efforts honored for the fourth consecutive year.

With the acquisition of Irvine Scientific, FujiFilm will have a full product line supporting customers supplying antibody drugs to assisted reproductive technologies and cell therapy.

The investment makes Idifarma one of only three companies in the world offering this type of contract development and manufacturing spray drying service.

Customers stand to benefit from broader services covering their API, drug product, regulatory CMC and bioanalysis requirements.

Expansion increases the facility’s manufacturing capacity by 200 million unidoses/year.

Global analysis will rank each major biomanufacturing country’s market growth potential, innovation and competitiveness.

Extensive range of ready-to-use culture media available in bottles and plates.

Additional capacity expansion across several of the company's sites also strengthens the company's global market leadership in spray drying.

Bio and generic demand reflective of wider trends in the market – with overseas investments now prospering.

Unique, single-use perfusion system offers a fast-track to intensified cell culture process development.

Four out of 10 of the top selling facial scrub brands use clay, sugar, salt or fruits as alternatives to microbeads.

Manufacturing high potency drugs - the challenges and innovations to mitigate the risks.

Noramco selects AFC for its infrastructure and analytical capabilities to help meet growing demand.

Partnership enables production volumes of NLAB Saga chromatography material to increase from tens of kilograms to tens of tonnes.

PF-04958242 is an AMPA receptor potentiator designed to facilitate neurotransmission.

MedPharm invests in $0.75 million cutting-edge instrumentation to further automated testing and expands workforce.

Experts forecast the personalised medicines, intelligent packaging and regulatory deadlines as the industry's biggest development.

The agreement includes the manufacture of 600 million enteric, chewable and film-coated tablets.

Licensing agreement enables Recipharm to co-develop new value-added medicines for its customers utilising Altus’ patented Intellitab and Flexitab drug delivery technologies.

ASEAN Economic Community and relaxed rules on foreign ownership driving increases in international investment and partnerships.

Expansions to meet safety requirements for GMO S2 and BSL-2 biological products.

Customers to have the option of one partner from concept to market for their encapsulated drug products

Proposed acquisition of Viralytics will add investigational oncolytic immunotherapy, Cavatak, to Merck's pipeline.

The SupaPore VPBA filter enabled 30% faster processing times than the company's current regime.

Gaining GLP/GMP accreditation to provide greater assurance of data integrity for clients looking to take their compounds to IND.

Agreement follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the US.

BASF's Hepaxa is the first product in the US specifically designed to address a buildup of fat in the liver in NAFLD patients.

The Centers of Excellence will allow custoners to access customer-centric solutions.

Vetter innovations in aseptic production increases the competitiveness of its customers.

The scientific, chemical and pharmaceutical expertise will cover end-to-end development services, ranging from development of the active compound to providing dossiers for marketing authorisation applications in all major geographies.

Expansion will accommodate new scientists to service the increase in demand for the company's formulation development, performance testing and manufacturing services.

Screening for new marine-derived functional ingredients and bringing new patented products to the market.

Packaging innovation shows a clear focus on patient compliance and ease-of-use.

New manufacturing paradigm will save 25% of total costs and the need for proteinaceous A & G resins.

What does a good supplier look like? Andrew Ramage, Microbiology Product Specialist at Cherwell Laboratories, advises how to take the guesswork out of the search.